🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Oragenics director Fred Telling sells $1,294 in common stock

Published 12/10/2024, 05:26 AM
OGEN
-

SARASOTA, Fla.—Fred Telling, a director at Oragenics Inc . (NYSE:OGEN), sold 3,597 shares of the company's common stock on December 6, according to a recent SEC filing. The shares were sold at an average price of $0.36 each, amounting to a total transaction value of $1,294. Following this sale, Telling holds 34,748 shares directly. The transaction comes as Oragenics shares have declined over 90% in the past year, with the stock currently trading near $0.35. According to InvestingPro analysis, the company maintains a strong cash position relative to debt, though it faces profitability challenges.

Oragenics, a pharmaceutical company based in Sarasota, Florida, continues to be active in the life sciences sector. The transaction was executed by Julio C. Esquivel, acting as Attorney-in-Fact for Fred Telling. InvestingPro analysis reveals 8 additional investment tips for OGEN, including key insights about its growth prospects and market position. Subscribers can access detailed Fair Value analysis and comprehensive financial metrics.

In other recent news, Oragenics Inc. announced the termination of its President's employment agreement and entered into a sales agreement with Dawson James Securities Inc. for an at-the-market offering of its common stock, potentially reaching up to $10,000,000 in aggregate sales. The company also granted stock options to President J. Michael Redmond and CFO Janet Huffman under its 2021 Equity Incentive Plan. In terms of clinical developments, Oragenics has progressed with ONP-002, a product candidate for the treatment of concussions, which has passed FDA-required cardiotoxicity tests and shown no evidence of causing DNA damage in preclinical studies. The company has also strengthened its leadership team with the appointments of Dr. William 'Frank' Peacock as Chief Clinical Officer and Dr. James 'Jim' Kelly as Chief Medical (TASE:PMCN) Officer. In addition, the company has rescheduled its 2023 Annual Meeting of Shareholders from August to December 2024. These are the recent developments for Oragenics Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.